Posted by Michael Wonder on 05 Apr 2018
NICE set to reject Roche's Ocrevus (ocrelizumab)
5 April 2018 - NICE has published an appraisal consultation document for ocrelizumab for the treatment of patients with relapsing multiple sclerosis.
Ocrelizumab is not recommended, within its marketing authorisation, for treating relapsing forms of multiple sclerosis in adults with active disease defined by clinical or imaging features.
Ocrelizumab at its current price is not cost effective compared with its comparators: beta interferons, dimethyl fumarate, glatiramer acetate and teriflunomide.
